Investigational drug · Phase 3
Zimberelimab
Also called: AB122, GS-0122, ZIM
Not approved by FDA. In 12 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
12
7 still active
All registered trials
74
Any phase or sponsor naming "Zimberelimab"
First trial start
2018
Aug 13, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zimberelimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lung Cancer
- Non Small Cell Lung Cancer
- Nonsquamous Non Small Cell Lung Cancer
- Squamous Non Small Cell Lung Cancer
- Biliary Tract Cancer
- Advanced or Metastatic Non-Small-Cell Lung Cancer
- Resectable Non-Small-Cell Lung Cancer
- Metastatic Urothelial Cancer
- Cervical Cancer
- Non-small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Cervical cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Zimberelimab" as an intervention, largest first.
Arcus Biosciences, Inc.Industry
NCT05568095 · 1,040 participants · Start Nov 21, 2022 · Primary completion Aug 28, 2026
Drug: Domvanalimab; Zimberelimab and 5 more · For: Advanced Upper Gastrointestinal Tract Adenocarcinoma
Sites: Los Angeles, California; Orange, California; Santa Monica, California · 168 sites in all
- Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05502237 · 1,021 participants · Start Oct 12, 2022 · Primary completion Jun 2028
Drug: Zimberelimab; Domvanalimab and 6 more · For: Non-small Cell Lung Cancer
Sites: Whittier, California; Washington D.C., District of Columbia; Tampa, Florida · 186 sites in all
- Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerPivotal-lookingRecruiting
Taiho Pharmaceutical Co., Ltd.Industry
NCT07710885 · 784 participants (planned) · Start Jun 24, 2026 · Primary completion Apr 30, 2030
Drug: Futibatinib; Zimberelimab and 4 more · For: Biliary Tract Cancer
Sites: Brisbane, Australia; Melbourne, Australia; Perth, Australia · 21 sites in all
Arcus Biosciences, Inc.Industry
NCT05536141 · 512 participants (planned) · Start Oct 26, 2022 · Primary completion Mar 2029
Drug: Casdatifan; Cabozantinib and 5 more · For: Clear Cell Renal Cell Carcinoma; Solid Tumors
Sites: Birmingham, Alabama; San Diego, California; Santa Monica, California · 25 sites in all
- Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT03547973 · 502 participants · Start Aug 13, 2018 · Primary completion Apr 2030
Drug: Sacituzumab Govitecan-hziy; Pembrolizumab and 7 more · For: Metastatic Urothelial Cancer
Sites: Tucson, Arizona; San Francisco, California; Littleton, Colorado · 128 sites in all
- A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical CancerPivotal-lookingRecruiting
Guangzhou Gloria Biosciences Co., Ltd.Industry
NCT05798819 · 424 participants (planned) · Start Apr 20, 2023 · Primary completion Dec 31, 2029
Drug: GLS-010; Placebo and 4 more · For: Persistent, Recurrent, or Metastatic Cervical Cancer
Sites: Shanghai, China
- Study With Various Immunotherapy Treatments in Participants With Lung CancerPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05676931 · 400 participants (planned) · Start Feb 21, 2023 · Primary completion Dec 2027
Drug: Domvanalimab; Quemliclustat and 3 more · For: Advanced Non-Small Cell Lung Cancer
Sites: Birmingham, Alabama; La Jolla, California; Hollywood, Florida · 53 sites in all
- A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesPivotal-lookingCompleted
Arcus Biosciences, Inc.Industry
NCT05329766 · 332 participants · Start Jun 10, 2022 · Primary completion Sep 7, 2026
Drug: Domvanalimab; Quemliclustat and 4 more · For: Gastrointestinal Tract Malignancies
Sites: Phoenix, Arizona; Los Angeles, California; Santa Monica, California · 43 sites in all
- Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid TumorsActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT05007782 · 304 participants · Start Aug 18, 2021 · Primary completion Dec 2028
Drug: Denikitug; Zimberelimab · For: Advanced Solid Tumor
Sites: La Jolla, California; Palo Alto, California; New Haven, Connecticut · 25 sites in all
- Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid TumorsCompleted
Guangzhou Gloria Biosciences Co., Ltd.Industry
NCT03713905 · 293 participants · Start Jul 1, 2017 · Primary completion Feb 28, 2022
Drug: GLS-010 · For: Advanced Solid Tumors
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Evaluating kinetic solubility - a comparative study of analytical approaches using UV-based evaluation methods.
Szolláth R, Bárdos V, Tzsér P, et al. · Eur J Pharm Sci 2026
- CRISPR/Cas9-mediated editing of the GhJAZ2 gene improves fiber length and lint percentage in Gossypium hirsutum L.
Saleem MS, Khan SH, Rana IA, et al. · GM Crops Food 2026
- NtJAZ4 and NtHD12 co-regulate the stigma epidermal development in Nicotiana tabacum.
Wang Q, Zhang S, Li Y, et al. · Plant Physiol Biochem 2026
- FaWRKY7 modulates jasmonate signaling responses and enhances strawberry fruit resistance to Botrytis cinerea.
Tong S, Wei M, Chen Y, et al. · J Exp Bot 2026
- Comparison of the pharmacokinetics and sedative effects of Zenalpha (medetomidine and vatinoxan) administered intramuscularly and oral transmucosally in dogs.
Lathan AW, Smith CK, Kleine SA, et al. · Am J Vet Res 2026
- Functional characterization of MfJAZ1 from Medicago falcata as a negative regulator of cold tolerance in transgenic Arabidopsis.
Chai L, Qian K, Yang H, et al. · Plant Physiol Biochem 2026
Also in development for Lung Cancer
- DomvanalimabAB154, GS-0154Phase 310 trials
Gilead Sciences · Lung Cancer, Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer
- zipalertinibTAS6417, CLN-081Phase 34 trials
Taiho Oncology, Inc. · Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations, Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
- BL-M14D1Phase 32 trials
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
- Atezolizumab followed by AtezolizumabPhase 31 trial
SystImmune Inc. · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma
- TilesizumabBGB-108Phase 31 trial
Qilu Pharmaceutical Co., Ltd. · Lung Cancer
- AB928Etrumadenant, ETRUMAPhase 24 trials
Arcus Biosciences, Inc. · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer
- HRS-4508Phase 23 trials
Jiangsu HengRui Medicine Co., Ltd. · Solid Tumor, Lung Cancer
- JDQ443OpnurasibPhase 23 trials
Novartis · Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation, Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.